New studies by the US Centers for Disease Control and Prevention indicate that the update Covid-19. Boosters are reducing a person’s risk of becoming ill with coronavirus by half.
The data show that the boosters continue to offer substantial protection against the currently circulating variants.
This near real-time data was collected by the federally funded Community. Access to Testing Enhancement programme, which administers covid-19 testing through pharmacies.
In fact, results from adults who were teste at participating pharmacies from 1 December to 13 January are included, according to CNN’s review.
CDC says vaccine boosters helpe prevent variant development
Of nearly 30,000 test results include in the analysis, more than 13,000 (47%) teste positive for covid-19.
More people who tested negative receive an update bivalent booster compared to those who teste positive.
On average, people in the study who had not receive a bivalent booster also receive. A dose of covid-19 vaccine in more than a year. That’s about the same as the national average, the study authors said.
The study results show that update boosters are most effective for younger adults.
CDC says vaccine boosters helpe prevent variant development
According to CDC senior epidemiologist and lead author of the study Ruth Link-Gelles. these vaccine effectiveness figures are averages. Because everyone is unique in terms of their underlying health, prior exposure to the virus and other factors, these estimates of vaccine effectiveness may not apply to the individual.
Timing of the bivalent vaccine
Link-Gelles explaine that it is too early to know how the protection of the bivalent booster and the behaviour of waning with these new two-strain injections works.
So far, there is little evidence of a decline in efficacy two to three months after people received their injections.
“It is too early, I think, to know how the decline will occur with the bivalent vaccine. We know from the older vaccines we see that protection decreases over time, especially against symptomatic infection. As with general protection, what we have seen in the past is that its protection lasts longer for more severe diseases,” Link-Gelles said.